Search Results
Aug 11, 2026, 17:21 ET Summary Notice to Stockholders of Big Rock Partners Acquisition Corp. as of June 8, 2021
(iii) defendant Alessandra Daigneault; and (iv) former defendants Steven Levine, David Nussbaum, BRAC Lending Group LLC, and EarlyBirdCapital, Inc. (the "EBC Defendants," and together with the Big Rock Defendants and Daigneault, the "Settling Defendants," and together with Plaintiff, the "Settling Parties")
More news about: Levi & Korsinsky, LLP
Jun 05, 2026, 19:25 ET Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Eastern BanksharesEBCFinancials
More news about: S&P Dow Jones Indices
May 30, 2026, 10:41 ET iQIYI International estreia no Rio2C, apresentando a plataforma de IA Nadou Pro e avanços de localização no Brasil
potencial significativo para se conectar com os espectadores locais."Durante o evento, a iQIYI International também destacou sua cooperação com a EBC e o lançamento de "To the Wonder" em parceria com a Red TAL, como parte de seus esforços mais amplos para levar conteúdo asiático ao público em
More news about: iQIYI International
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Verzenio as a CDK4/6 inhibitor. In high-risk EBC, Verzenio has shown a persistent and deepening benefit beyond the two-year treatment period in the monarchE trial, an adjuvant study designed specifically to investigate a CDK4/6 inhibitor in a node-positive, high-risk EBC population.6 In metastatic
More news about: Eli Lilly and Company
May 20, 2026, 08:38 ET dxFeed Introduces Event-Based Contracts Gateway with Kalshi Support
Event-Based Contracts (EBC) Market Data Feed with the addition of Kalshi — one of the most prominent venues in the prediction markets space. The new gateway brings
More news about: dxFeed
May 19, 2026, 21:30 ET Global Automotive Brake Shims Market | USA, Europe, Japan, South Korea Lead | Bosch, Brembo, Continental Drive Next-Generation NVH and Smart Braking Technologies
Brembo S.p.A., and Akebono Brake Industry Co., Ltd., alongside companies such as Federal-Mogul Corporation, Nisshinbo Holdings Inc., Continental AG, EBC Brakes, and DSS Brakes.Competition is increasingly defined by:Development of AI-enabled and sensor-integrated brake shim
More news about: Future Market Insights
May 01, 2026, 18:12 ET Rockefeller Foundation Celebrates 60th Anniversary of Nairobi Office and 100 Years of Impact in Africa
16% to 28% in 2025, according to the EBC Financial Group. At the same time, the continent is home to 11 of the 15 fastest-growing economies globally, and it is estimated that by the end of this
More news about: The Rockefeller Foundation
Apr 22, 2026, 18:30 ET Prestige Biopharma IDC Files Patent for Next-Generation Antibody Delivery Platform 'IDC224'… Driving Innovation in Subcutaneous (SC) Formulations
medication. Tuznue® is indicated for the treatment of patients with HER2-positive metastatic breast cancer (MBC), HER2-positive early breast cancer (EBC), and HER2-positive metastatic gastric cancer (MGC).About Prestige BiopharmaEstablished in 2015 in Singapore, Prestige Biopharma
More news about: Prestige Biopharma
Mar 16, 2026, 08:00 ET Over 1,400 High School Scholars Earn National Honors for Performance in Top College Courses
RatraCultural Academy for the Arts and Sciences, Principal AlexisDigital Arts and Cinema Technology High School, Principal MeconiEBC High School for Public Service - Bushwick, Principal EspinozaEpic High School - South, Principal MohanFlushing International High School,
More news about: National Education Opportunity Network
Feb 18, 2026, 01:44 ET Photocure ASA: Results for the fourth quarter of 2025
https://mb.cision.com/Public/17498/4309132/9d2775c6e58ebc9f.pdfPHO Q4 2025 REPORT
More news about: Photocure
Feb 18, 2026, 01:40 ET Photocure ASA: Results for the fourth quarter of 2025
https://mb.cision.com/Public/17498/4309132/9d2775c6e58ebc9f.pdfPHO Q4 2025 REPORT
More news about: Photocure
Feb 09, 2026, 09:00 ET HOLDCO ASSET MANAGEMENT TO PRESENT AT UBS FINANCIAL SERVICES CONFERENCE IN KEY BISCAYNE, FLORIDA; RELEASES PRESENTATION
following banks: KeyCorp (NYSE: KEY), Comerica Inc. (NYSE: CMA), Columbia Banking System, Inc. (NASDAQ-GS: COLB), Eastern Bankshares, Inc. (NASDAQ-GS: EBC), and First Interstate BancSystem, Inc. (NASDAQ-GS: FIBK). It also provides updates on four behind-the-scenes "soft activism" engagements with respect
More news about: HoldCo Asset Management
Dec 12, 2025, 11:45 ET Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
ABC (32%), following disease recurrence on or within 12 months of completing adjuvant AI, with or without CDK4/6 inhibitor for early breast cancer (EBC), or as second line (2L) treatment for ABC (64%), following progression on AI, with or without CDK4/6 inhibitor as initial therapy for ABC. Primary endpoints
More news about: Eli Lilly and Company
Dec 10, 2025, 14:02 ET Menarini Group presenta datos de combinación de fase 2 de Elacestrant (ORSERDU®) en pacientes con cáncer de mama metastásico (CMM) ER+, con HER2 en el Simposio de Cáncer de Mama 2025 en San Antonio
mama en estadio temprano con ganglios positivos, receptores de estrógeno positivos (ER+), HER2-negativos (HER2-), cáncer de mama en estadio temprano (eBC, por sus siglas en inglés) con alto riesgo de recurrencia en un estudio de fase 3 global, multicéntrico, aleatorizado y abierto.Número del
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 23:19 ET Il Gruppo Menarini presenta i dati di fase 2 sulla combinazione di elacestrant (ORSERDU®) in pazienti affetti da carcinoma mammario metastatico (mBC) ER+, HER2- al Simposio sul cancro al seno di San Antonio del 2025
Versus Standard Endocrine Therapy (ET) in Women and Men With Node-positive, Estrogen Receptor-positive (ER+), HER2-negative (HER2-), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-label Phase 3 Study.Numero abstract: 1276Data e
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 14:24 ET Menarini Group 於 2025 年聖安東尼奧乳癌研討會公佈 Elacestrant (ORSERDU®) 針對 ER+、HER2- 轉移性乳癌 (mBC) 患者的第 2 期聯合治療數據
ABC發表演講者：Mertixell Bellet簡報題目：ELEGANT：一項在全球多中心進行的隨機、開放標籤第 3 期研究，比較 Elacestrant 與標準內分泌治療 (ET) 在淋巴結陽性、雌激素受體陽性 (ER+)、HER2 陰性 (HER2-) 且具高復發風險的早期乳癌 (eBC) 女性及男性患者中的療效。摘要編號：1276發表日期及時間：2025 年 12 月 11 日（星期四），下午 12:30 – 2:00地點：Henry B. Convention Center發表演講者：Aditya
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 11:38 ET El Grupo Menarini presenta datos de la combinación de fase 2 de Elacestrant (ORSERDU®) en cáncer de mama
Versus Standard Endocrine Therapy (ET) in Women and Men With Node-positive, Estrogen Receptor-positive (ER+), HER2-negative (HER2-), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-label Phase 3 Study. (ELEGANT: Elacestrant versus terapia endocrina estándar
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 09:49 ET 메나리니 그룹, 2025 샌안토니오 유방암 심포지엄에서 엘라세스트란트(ORSERDU)®의 ER+, HER2- 전이성 유방암(mBC) 환자 대상 2상 병용 요법 데이터 발표
Versus Standard Endocrine Therapy (ET) in Women and Men With Node-positive, Estrogen Receptor-positive (ER+), HER2-negative (HER2-), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-label Phase 3 Study)초록 번호: 1276발표 날짜 및 시간: 2025년
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 15:17 ET Le groupe Menarini présente les données de la phase 2 sur l'association d'Elacestrant (ORSERDU®) chez des patientes atteintes d'un cancer du sein métastatique (mBC) ER+, HER2- lors du 2025 San Antonio Breast Cancer Symposium
présentation : ELEGANT : Elacestrant versus une thérapie endocrinienne standard (ET) chez les femmes et les hommes atteints d'un cancer du sein précoce (eBC) avec un risque élevé de récidive, avec envahissement ganglionnaire, récepteurs d'œstrogènes positifs (ER+), HER2 négatifs (HER2-), dans une étude de
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 14:47 ET Menarini Group präsentiert Daten zur Phase-2-Kombination von Elacestrant (ORSERDU®) bei Patientinnen mit ER+, HER2- metastasiertem Brustkrebs (mBC) auf dem San Antonio Breast Cancer Symposium 2025
endokrinen Standardtherapie (ET) bei Frauen und Männern mit Knoten-positivem, Östrogenrezeptor-positivem (ER+), HER2-negativem (HER2-), frühem Brustkrebs (eBC) mit hohem Rezidivrisiko in einer globalen, multizentrischen, randomisierten, offenen Phase-3-Studie.Abstract-Nummer: 1276Datum
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:41 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
Versus Standard Endocrine Therapy (ET) in Women and Men With Node-positive, Estrogen Receptor-positive (ER+), HER2-negative (HER2-), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-label Phase 3 Study.Abstract Number: 1276Presentation
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:30 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
Versus Standard Endocrine Therapy (ET) in Women and Men With Node-positive, Estrogen Receptor-positive (ER+), HER2-negative (HER2-), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-label Phase 3 Study.Abstract Number: 1276Presentation
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 25, 2025, 20:16 ET Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America
medication. Tuznue® is indicated for the treatment of patients with HER2-positive metastatic breast cancer (MBC), HER2-positive early breast cancer (EBC), and HER2-positive metastatic gastric cancer (MGC).About Prestige BiopharmaEstablished in 2015 in Singapore, Prestige Biopharma
More news about: Prestige Biopharma Limited
Nov 24, 2025, 16:30 ET Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
interstitial lung disease (ILD) or pneumonitis can occur in patients treated with Verzenio and other CDK4/6 inhibitors. In Verzenio-treated patients in EBC (monarchE), 3% of patients experienced ILD or pneumonitis of any grade: 0.4% were Grade 3 or 4 and there was one fatality (0.1%). In Verzenio-treated
More news about: Eli Lilly and Company
Nov 13, 2025, 23:32 ET EBC亮相台北國際金融博覽會，以全球實力引領金融科技發展
View original content:https://www.prnewswire.com/apac/zh/news-releases/ebc-302615241.html SOURCE EBC 金融集團
More news about: EBC 金融集團